Brief: Obseva Announces Topline Results For Linzagolix

Obseva SA

06/01/2022 06:08

Jan 6 (Reuters) - OBSEVA SA  OBSN.S :
    * OBSEVA ANNOUNCES POSITIVE TOPLINE RESULTS FOR LINZAGOLIX
200 MG
WITH ADD-BACK THERAPY IN THE PHASE 3 EDELWEISS 3 TRIAL IN
PATIENTS WITH MODERATE-TO-SEVERE ENDOMETRIOSIS-ASSOCIATED PAIN
    * ONCE DAILY LINZAGOLIX 200 MG WITH ABT MET BOTH CO-PRIMARY
EFFICACY OBJECTIVES, DEMONSTRATING REDUCTIONS IN DYSMENORRHEA
AND NON-MENSTRUAL PELVIC PAIN VERSUS PLACEBO AT 3 MONTHS; SHOWED
STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS
VERSUS PLACEBO IN RANKED SECONDARY ENDPOINTS OF DYSMENORRHEA,
NON-MENSTRUAL PELVIC PAIN, DYSCHEZIA, OVERALL PELVIC PAIN, AND
ABILITY TO PERFORM DAILY ACTIVITIES AT 6 MONTHS
    * ADDITIONAL DATA FROM POST-TREATMENT FOLLOW-UP OF EDELWEISS
3 ARE
EXPECTED IN 2Q 2022 AND FROM POST-TREATMENT FOLLOW-UP OF
EXTENSION STUDY IN 4Q 2022-

Source text for Eikon:  ID:nGNE5q2f26 
Further company coverage:  OBSN.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))